LGALS3BP Knockout cell line (AC16)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

LGALS3BP (galectin 3 binding protein) encodes a protein that interacts with galectins and a macrophage-associated lectin. Through these interactions, LGALS3BP may modulate cell-cell and cell-matrix interactions. It has also been implicated in immune responses associated with natural killer and lymphokine-activated killer cell cytotoxicity, linking the protein to extracellular signaling and immune cell interactions.

Human cardiac ventricular cells are represented by AC16, an immortalized cell line derived from primary human ventricular tissue. The cells were generated by fusion of primary adult ventricular cardiomyocytes with a human fibroblast-like cell line carrying a temperature-sensitive SV40 large T antigen. AC16 exhibits cardiac-related characteristics and is used as an in vitro model for studies of human cardiomyocyte biology.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.